Results 51 to 60 of about 121,777 (350)
Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
Li‐Tsung Lin +2 more
wiley +1 more source
Intravenous immunoglobulin therapy for autoimmune diseases
Autoimmunity, 2009 Therapeutic approaches for autoimmune diseases are primarily based on suppressive measures that down regulate an over productive immune system. The increasing availability of modern biological therapies has advanced the ability to target and to neutralize essential components of the immune response without experiencing the hazardous adverse effects ...
Yoav, Arnson +2 more
openaire +2 more sources
Serum levels of matrix metalloproteinases-2 and-9 and their tissue inhibitors in inflammatory neuromuscular disorders [PDF]
, 2006 We monitored serum levels of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) before and during intravenously applied immunoglobulin (IVIG) therapy in 33 patients with chronic immune-mediated neuropathies and myopathies and 15 ...
B.G.H. Schoser +15 more
core +1 more source
Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic drug monitoring under eculizumab.
Lea Gerischer +14 more
wiley +1 more source
SAGE Open Medical Case Reports, 2017 Context: Immunoglobulin G2 deficiency that persists beyond the age of 6 years is likely to be permanent. Case report: We report on a young Japanese female, diagnosed as having immunoglobulin G2 deficiency and low anti-pneumococcal immunoglobulin G2 ...
Masayoshi Shinjoh +3 more
doaj +1 more source
Медична наука України, 2017 At hepatology intravenous immunoglobulin was tested in several areas, but the evidence base of effectiveness is different at each nosology and often insufficient for routine use of the drug.
D.V. Maltsev, D.P. Muzyca
doaj +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Background Myasthenia gravis (MG) is a rare disorder characterized by fluctuating muscle weakness with potential life‐threatening crises. Timely interventions may be delayed by limited access to care and fragmented documentation. Our objective was to develop predictive algorithms for MG deterioration using multimodal telemedicine data ...
Maike Stein +7 more
wiley +1 more source
The Turkish Journal of Pediatrics, 2016 Intravenous immunoglobulin therapy is standard for Kawasaki disease (KD) treatment; however, anaphylactic reactions to immunoglobulins are a risk in KD patients with selective IgA deficiency (sIgAD).
Tatsuya Anzai +4 more
doaj +1 more source
Frontiers in Pediatrics, 2023 Multisystem inflammatory syndrome in children (MIS-C) has been widely reported, mainly in Western countries. The clinical features of MIS-C and Kawasaki disease are similar. The latter is common in Asian countries, including Japan.
Takanori Suzuki +6 more
doaj +1 more source
Aseptic Meningitis Associated with Intravenous Immunoglobulin [PDF]
, 2014 Aseptic meningitis can be an adverse drug reaction to intravenous immunoglobulin. We describe a previously healthy 4-yearold boy, admitted for idiopathic thrombocytopaenic purpura. He received two infusions of intravenous immunoglobulin.
Cunha, F +3 more
core